Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754603 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Peripherally induced movement disorders in the stomatognathic system after oral surgical or dental procedures.
Oral Maxillofac Surg
December 2024
Department of Oral and Maxillofacial Surgery, National Hospital Organization, Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan.
Objectives: Peripherally induced movement disorders (PIMD) are hyperkinetic movement disorders that can occur after injury to a part of the body. This study aimed to identify PIMD in the stomatognathic system following dental or oral surgical procedures.
Materials And Methods: A total of 229 patients with PIMD (144 women and 85 men; mean age: 53.
Activation of mGlu 2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism.
Behav Pharmacol
June 2024
Neurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro).
LY-404,039 is an orthosteric agonist at metabotropic glutamate 2 and 3 (mGlu 2/3 ) receptors, with a possible additional agonist effect at dopamine D 2 receptors. LY-404,039 and its pro-drug, LY-2140023, have previously been tested in clinical trials for psychiatric indications and could therefore be repurposed if they were shown to be efficacious in other conditions. We have recently demonstrated that the mGlu 2/3 orthosteric agonist LY-354,740 alleviated L-3,4-dihydroxyphenylalanine (L-DOPA)-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat without hampering the anti-parkinsonian action of L-DOPA.
View Article and Find Full Text PDFIpsilateral orolingual angioedema following rhTNK-tPA administration for acute ischemic stroke.
Am J Emerg Med
March 2024
Department of Neurology, Taixing People's Hospital, Taixing, Jiangsu 225400, China. Electronic address:
Recombinant human tenecteplase tissue-type plasminogen activator (rhTNK-tPA), a genetically modified variant of conventional alteplase with longer half-life and higher fibrin specificity, has now emerged as a reasonable choice for thrombolytic treatment of acute ischemic stroke (AIS) in China. Orolingual angioedema is a rare but potentially life-threatening complication of intravenous thrombolysis. Currently, there is no documented evidence of orolingual angioedema occurring after thrombolysis with rhTNK-tPA.
View Article and Find Full Text PDFTenecteplase-associated orolingual angioedema: A case report and literature review.
Am J Health Syst Pharm
April 2024
Department of Pharmacy, Licking Memorial Hospital, Newark, OH, USA.
Article Synopsis
- Orolingual angioedema (OA) is a serious but rare side effect of thrombolytic therapy, specifically after administering tenecteplase, requiring prompt treatment.
- A 67-year-old male patient experienced OA after receiving tenecteplase for an acute stroke, and initial treatments with antihistamines and steroids were ineffective.
- Despite the administration of a C1 esterase inhibitor, the patient's condition worsened, leading to intubation, but he eventually improved and was extubated after 30 hours, highlighting the need for quick and effective management of OA in such cases.
Icatibant averting mechanical ventilation in acute ischemic stroke patient with alteplase-induced orolingual angioedema.
Eur J Neurol
April 2024
Second Department of Neurology, School of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Background And Purpose: Orolingual angioedema (OA) represents a rare but life-threatening complication among patients with acute ischemic stroke treated with intravenous thrombolysis with alteplase. Novel agents, including icatibant, are recommended in resistant patients with alteplase-induced OA who have failed to respond to first-line therapies including corticosteroids, antihistamines, and/or adrenaline.
Methods: We present a patient with alteplase-induced OA who showed substantial clinical improvement following the administration of icatibant.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!